The popularity of copyright’s blockbuster initially sparked a boom for pharma, however recent changes present a complicated outlook for those considering a stake. Off-patent competitors are eating into earnings, and ongoing litigation add more risk to the situation. While specific companies may still benefit from complementary products, the gener